Bajaj Finserv Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹341 Cr

Expense Ratio

0.67%

ISIN

INF0QA701AB9

Minimum SIP

₹500

Exit Load

1.00%

Inception Date

27 Dec 2024

About this fund

This fund has been in existence for 7 months and 30 days, having been launched on 27-Dec-24.
As of 25-Aug-25, it has a Net Asset Value (NAV) of ₹9.98, Assets Under Management (AUM) of 341.35 Crores, and an expense ratio of 0.67%.

Bajaj Finserv Healthcare Fund Direct Growth has given a CAGR return of -0.21% since inception.
The fund's asset allocation comprises around 96.73% in equities, 0.00% in debts, and 3.27% in cash & cash equivalents.
You can start investing in Bajaj Finserv Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

-0.21%

— (Cat Avg.)

Portfolio Summaryas of 31st July 2025

Equity	₹330.18 Cr	96.73%
Others	₹11.17 Cr	3.27%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Divi's Laboratories Ltd	Equity	₹27.09 Cr	7.94%
Sun Pharmaceuticals Industries Ltd	Equity	₹25.54 Cr	7.48%
Apollo Hospitals Enterprise Ltd	Equity	₹20.51 Cr	6.01%
Cipla Ltd	Equity	₹18.16 Cr	5.32%
Biocon Ltd	Equity	₹12.82 Cr	3.76%
Glenmark Pharmaceuticals Ltd	Equity	₹11.76 Cr	3.45%
Emcure Pharmaceuticals Ltd	Equity	₹11.56 Cr	3.39%
Dr Reddy's Laboratories Ltd	Equity	₹11.49 Cr	3.37%
Syngene International Ltd	Equity	₹11.08 Cr	3.25%
Fortis Healthcare Ltd	Equity	₹10.92 Cr	3.20%
Piramal Pharma Ltd	Equity	₹10.74 Cr	3.15%
Net Receivables / (Payables)	Cash	₹10.59 Cr	3.10%
Dr. Lal PathLabs Ltd	Equity	₹10.54 Cr	3.09%
Neuland Laboratories Ltd	Equity	₹10.24 Cr	3.00%
Aurobindo Pharma Ltd	Equity	₹9.88 Cr	2.89%
Pfizer Ltd	Equity	₹8.48 Cr	2.48%
Torrent Pharmaceuticals Ltd	Equity	₹8.26 Cr	2.42%
Ipca Laboratories Ltd	Equity	₹7.44 Cr	2.18%
Lupin Ltd	Equity	₹7 Cr	2.05%
Vijaya Diagnostic Centre Ltd	Equity	₹6.63 Cr	1.94%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹6.34 Cr	1.86%
Godrej Consumer Products Ltd	Equity	₹6.3 Cr	1.84%
Sanofi Consumer Healthcare India Ltd	Equity	₹6.22 Cr	1.82%
Abbott India Ltd	Equity	₹5.98 Cr	1.75%
Zydus Wellness Ltd	Equity	₹5.6 Cr	1.64%
Hindustan Unilever Ltd	Equity	₹5.46 Cr	1.60%
Medi Assist Healthcare Services Ltd	Equity	₹5.36 Cr	1.57%
Alkem Laboratories Ltd	Equity	₹4.81 Cr	1.41%
Medplus Health Services Ltd	Equity	₹4.81 Cr	1.41%
Emami Ltd	Equity	₹4.53 Cr	1.33%
Rainbow Childrens Medicare Ltd	Equity	₹4.5 Cr	1.32%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹4.36 Cr	1.28%
Jubilant Pharmova Ltd	Equity	₹4.18 Cr	1.22%
Shaily Engineering Plastics Ltd	Equity	₹3.94 Cr	1.15%
Alembic Pharmaceuticals Ltd	Equity	₹3.91 Cr	1.14%
Mankind Pharma Ltd	Equity	₹3.73 Cr	1.09%
AstraZeneca Pharma India Ltd	Equity	₹3 Cr	0.88%
Marico Ltd	Equity	₹2.24 Cr	0.66%
PB Fintech Ltd	Equity	₹1.78 Cr	0.52%
Nestle India Ltd	Equity	₹1.56 Cr	0.46%
Neogen Chemicals Ltd	Equity	₹1.45 Cr	0.43%
Clearing Corporation Of India Ltd	Cash - Repurchase Agreement	₹0.57 Cr	0.17%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹297.33 Cr	87.10%
Consumer Defensive	₹25.68 Cr	7.52%
Basic Materials	₹5.39 Cr	1.58%
Financial Services	₹1.78 Cr	0.52%

Risk & Performance Ratios

Fund Managers

Nimesh Chandan

Since December 2024

Siddharth Chaudhary

Since December 2024

Sorbh Gupta

Since December 2024

Additional Scheme Detailsas of 31st July 2025

ISIN

INF0QA701AB9

Expense Ratio

0.67%

Exit Load

1.00%

Fund Size

₹341 Cr

Age

7 months

Lumpsum Minimum

₹500

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.4%	1.0%	₹670.42 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.3%	1.0%	₹670.42 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹341.35 Cr	-
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹341.35 Cr	-
PGIM India Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹112.33 Cr	-
PGIM India Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹112.33 Cr	-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹409.43 Cr	14.8%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹409.43 Cr	16.9%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹10.65 Cr	5.0%
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹485.27 Cr	6.2%
Kotak Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹485.27 Cr	4.4%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹1936.05 Cr	13.7%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹1936.05 Cr	15.1%
Nippon India Pharma Fund Direct Growth Very High Risk	0.9%	1.0%	₹8736.57 Cr	4.0%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.9%	1.0%	₹6103.96 Cr	8.8%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.0%	1.0%	₹6103.96 Cr	9.7%
DSP Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹3190.15 Cr	4.9%
DSP Healthcare Fund Regular Growth Very High Risk	1.9%	0.0%	₹3190.15 Cr	3.5%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹90.98 Cr	6.5%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹90.98 Cr	5.2%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹409.22 Cr	-10.3%
quant Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹409.22 Cr	-11.8%
UTI Healthcare Fund Direct Growth Very High Risk	1.3%	1.0%	₹1146.13 Cr	9.3%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4026.55 Cr	11.6%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹1339.00 Cr	3.3%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹1339.00 Cr	4.9%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹146.40 Cr	5.1%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4026.55 Cr	10.4%
Nippon India Pharma Fund Regular Growth Very High Risk	1.8%	1.0%	₹8736.57 Cr	3.1%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1146.13 Cr	8.2%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹20.49 Cr	4.9%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹942.04 Cr	-0.3%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2908.21 Cr	3.4%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2908.21 Cr	4.9%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹235.68 Cr	1.2%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹235.68 Cr	3.1%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹36.57 Cr	5.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹871.69 Cr	1.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹871.69 Cr	2.8%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹21.23 Cr	6.7%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth?

The NAV of Bajaj Finserv Healthcare Fund Direct Growth, as of 25-Aug-2025, is ₹9.98.

What is the portfolio composition of Bajaj Finserv Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 96.73% in equities, 0.00% in bonds, and 3.27% in cash and cash equivalents.

Who manages the Bajaj Finserv Healthcare Fund Direct Growth?

The fund managers responsible for Bajaj Finserv Healthcare Fund Direct Growth are:-

Nimesh Chandan
Siddharth Chaudhary
Sorbh Gupta

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹341 Cr

Expense Ratio

0.67%

ISIN

INF0QA701AB9

Minimum SIP

₹500

Exit Load

1.00%

Inception Date

27 Dec 2024

Risk Level

Your principal amount will be at Very High Risk